Heather Wakelee

Clinical Trials

• Recruiting Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
• Recruiting Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
• Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
• Recruiting Molecular Analysis of Thoracic Malignancies
• Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
• Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
• Recruiting Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
• Not Recruiting Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
• Recruiting Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
• Not Recruiting Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
• Recruiting Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
• Recruiting Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
• Recruiting Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
• Not Recruiting Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
• Not Recruiting Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
• Recruiting Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) Non-Small Cell Lung Cancer (NSCLC)
• Recruiting A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
• Recruiting A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
• Recruiting Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
• Recruiting Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
• Recruiting BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
• Recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
• Not Recruiting Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
• Not Recruiting CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
• Not Recruiting Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
• Not Recruiting AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
• Not Recruiting Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
• Not Recruiting A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
• Not Recruiting PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
• Not Recruiting An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
• Not Recruiting A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma
• Not Recruiting Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
• Not Recruiting CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
• Not Recruiting Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
• Not Recruiting Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
• Not Recruiting Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer
• Not Recruiting Phase II Trial of Bevacizumab in Combination With Pemetrexed as 2nd Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer
• Not Recruiting Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
• Not Recruiting A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
• Not Recruiting A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
• Not Recruiting Study of XL647 Administered Orally Daily to Patients With Solid Tumors
• Not Recruiting Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
• Not Recruiting Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell)
• Not Recruiting A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
• Not Recruiting A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
• Not Recruiting Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
• Not Recruiting Radiation Therapy in Preventing CNS Metastases in Patients With Non-Small Cell Lung Cancer
• Not Recruiting Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
• Not Recruiting An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
• Not Recruiting An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
• Not Recruiting Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
• Not Recruiting Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer
• Not Recruiting A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
• Not Recruiting A Study of Enzastaurin and Erlotinib in Patients With Solid Tumors and Lung Cancer
• Not Recruiting ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain
• Not Recruiting Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
• Not Recruiting A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC.
• Not Recruiting A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
• Not Recruiting Study of GDC-0973/XL518 in Patients With Solid Tumors
• Not Recruiting Immunobiology of Cancer
• Not Recruiting Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
• Not Recruiting Phase 1 Trial of Oral Ixabepilone
• Not Recruiting Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
• Not Recruiting Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
• Recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
• Recruiting Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
• Recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
• Recruiting Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
• Recruiting Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
• Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
• Recruiting Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Recruiting A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
• Recruiting Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
• Recruiting Phase IIa Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
• Recruiting A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
• Recruiting ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
• Recruiting 4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
• Recruiting Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
• Not Recruiting Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
• Recruiting Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
• Not Recruiting Phase I Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)